Delfi aims for a cheaper liquid biopsy

Blood tests for solid tumours having been around for several years now, any new entrant into the liquid biopsy space is going to need a new angle. Fortunately for its generous venture backers, Delfi Diagnostics has one: the group believes it can price its cancer test well below those already on the market.